BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 18644518)

  • 1. Chemotherapy-induced cardiotoxicity in women.
    Dempsey KS
    Crit Care Nurs Clin North Am; 2008 Sep; 20(3):343-50. PubMed ID: 18644518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy-induced cardiotoxicity in women.
    Dempsey KS
    Heart Fail Clin; 2011 Jul; 7(3):427-35. PubMed ID: 21749894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary?
    Castrellon AB; Glück S
    Clin Adv Hematol Oncol; 2008 Sep; 6(9):666-72. PubMed ID: 18827789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversibility of trastuzumab cardiotoxicity: is the concept alive and well?
    Ewer MS; Tan-Chiu E
    J Clin Oncol; 2007 Dec; 25(34):5532-3; author reply 5533-4. PubMed ID: 18048835
    [No Abstract]   [Full Text] [Related]  

  • 5. Trastuzumab-related cardiotoxicity following anthracycline-based adjuvant chemotherapy: how worried should we be?
    Morris PG; Hudis CA
    J Clin Oncol; 2010 Jul; 28(21):3407-10. PubMed ID: 20530269
    [No Abstract]   [Full Text] [Related]  

  • 6. Re: Therapy Insight: anthracyclines and trastuzumab--the optimal management of cardiotoxic side effects.
    Magné N; Chargari C
    Nat Clin Pract Oncol; 2008 Nov; 5(11):E1. PubMed ID: 18957967
    [No Abstract]   [Full Text] [Related]  

  • 7. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility.
    Telli ML; Hunt SA; Carlson RW; Guardino AE
    J Clin Oncol; 2007 Aug; 25(23):3525-33. PubMed ID: 17687157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiac risks in multimodal breast cancer treatment.
    Budach W
    Strahlenther Onkol; 2007 Dec; 183 Spec No 2():9-10. PubMed ID: 18166997
    [No Abstract]   [Full Text] [Related]  

  • 9. [Therapy concept: herceptin with anthracyclines].
    Untch M
    Onkologie; 2002 Dec; 25 Suppl 5():19-21; discussion 21. PubMed ID: 23573616
    [No Abstract]   [Full Text] [Related]  

  • 10. Troponin I provides insight into cardiotoxicity and the anthracycline-trastuzumab interaction.
    Ewer MS; Ewer SM
    J Clin Oncol; 2010 Sep; 28(25):3901-4. PubMed ID: 20679626
    [No Abstract]   [Full Text] [Related]  

  • 11. Trastuzumab before breast surgery? Large trial says yes but does not quell debate.
    Rowan K
    J Natl Cancer Inst; 2009 Apr; 101(7):448-9. PubMed ID: 19318626
    [No Abstract]   [Full Text] [Related]  

  • 12. Never use anthracyclines with trastuzumab: it is time to reconsider the taboo.
    Gianni L
    Breast Cancer Res Treat; 2009 Oct; 117(3):599-601. PubMed ID: 19387827
    [No Abstract]   [Full Text] [Related]  

  • 13. Therapy Insight: anthracyclines and trastuzumab--the optimal management of cardiotoxic side effects.
    Popat S; Smith IE
    Nat Clin Pract Oncol; 2008 Jun; 5(6):324-35. PubMed ID: 18364726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiotoxicity associated with the use of trastuzumab in breast cancer patients.
    Perik PJ; de Korte MA; van Veldhuisen DJ; Gietema JA; Sleijfer DT; de Vries EG
    Expert Rev Anticancer Ther; 2007 Dec; 7(12):1763-71. PubMed ID: 18062750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The incidence of symptomatic thromboembolism in patients receiving adjuvant anthracycline-based chemotherapy for early stage breast cancer.
    Nolan L; Darby A; Boleti K; Simmonds P
    Breast; 2011 Apr; 20(2):151-4. PubMed ID: 20970333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controversies in the use of adjuvant trastuzumab (Herceptin).
    Chowdhury S; Pickering L; Ellis P
    J Br Menopause Soc; 2006 Dec; 12(4):172-4. PubMed ID: 17178019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes.
    Gianni L; Salvatorelli E; Minotti G
    Cardiovasc Toxicol; 2007; 7(2):67-71. PubMed ID: 17652806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment.
    Ewer MS; Vooletich MT; Durand JB; Woods ML; Davis JR; Valero V; Lenihan DJ
    J Clin Oncol; 2005 Nov; 23(31):7820-6. PubMed ID: 16258084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiac toxicity associated with anthracycline-containing chemotherapy in older women with breast cancer.
    Du XL; Xia R; Liu CC; Cormier JN; Xing Y; Hardy D; Chan W; Burau K
    Cancer; 2009 Nov; 115(22):5296-308. PubMed ID: 19672997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiotoxicity of systemic agents used in breast cancer.
    Ades F; Zardavas D; Pinto AC; Criscitiello C; Aftimos P; de Azambuja E
    Breast; 2014 Aug; 23(4):317-28. PubMed ID: 24794210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.